TCGA-AN-A04C-01A-21R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.480
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.410
- OXIDATIVE_PHOSPHORYLATION+0.400
- SPERMATOGENESIS+0.220
- MTORC1_SIGNALING+0.210
- DNA_REPAIR+0.200
- XENOBIOTIC_METABOLISM+0.180
- FATTY_ACID_METABOLISM+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- UV_RESPONSE_DN-0.430
- INTERFERON_GAMMA_RESPONSE-0.410
- TGF_BETA_SIGNALING-0.350
- PROTEIN_SECRETION-0.320
- ANGIOGENESIS-0.280
- COMPLEMENT-0.280
- ESTROGEN_RESPONSE_EARLY-0.280
- INFLAMMATORY_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-AAMZ-01A-11R-A42T-07 | — | — | 0.888 |
| 2 | TCGA-22-4613-01A-01R-1443-07 | — | cohortSQ2 | 0.885 |
| 3 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.873 |
| 4 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.870 |
| 5 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.868 |
| 6 | C3N-00555 | — | cohortSQ2 | 0.867 |
| 7 | TCGA-4Z-AA87-01A-11R-A39I-07 | — | — | 0.864 |
| 8 | SRR6013549 | — | cohortSQ2 | 0.861 |
| 9 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.860 |
| 10 | C3N-01017 | — | cohortSQ2 | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |